Heel (Germany)

Historically, concerns about hypermagnesemia led to the reduction of dialysate magnesium (dMg) concentrations to below 0.75 mmol/L, effectively minimizing related adverse events. However, findings in recent years indicate that hypomagnesemia, defined as serum magnesium (sMg) levels below 0.7 mmol/L, has become more prevalent and a greater concern among dialysis patients, and has been associated with severe clinical outcomes, including vascular calcification and elevated mortality rates. Despite its significance, hypomagnesemia is often overlooked in clinical practice. This review highlights the critical importance of sMg levels in patients undergoing peritoneal dialysis (PD), particularly focusing on hypomagnesemia and hypermagnesemia. While causality has not been definitively established, evidence from the literature suggests that sMg levels should be monitored regularly and that increasing dMg concentrations from 0.25 to 0.5 or 0.75 mmol/L may help prevent hypomagnesemia, alongside nutritional management. Considering the impact of dMg on serum magnesium levels, and acknowledging the variability in reported outcomes, careful selection and individualization of dMg concentrations have the potential to impact clinical outcomes in PD patients.

What is this summary about?This is a summary of an article discussing the results of the TRAUMED trial, which was originally published in the Journal of Clinical Medicine. This trial studied how well Tr14 gel helped with ankle sprains compared with either a dummy treatment (placebo) or a common painkiller called diclofenac.What were the results of this trial, and what do they mean?The results of this trial showed that Tr14 was effective at reducing pain caused by an acute or sudden ankle sprain compared with placebo and worked just as well as diclofenac. The results also suggested that Tr14 led to faster pain relief and improved foot and ankle function compared with placebo and was at least as effective as diclofenac.Clinical Trial Registration:NCT06192420

Secondary lymphedema is a life-long disease of painful tissue swelling that often follows axillary lymph node dissection to treat breast cancer. It is hypothesized that poor lymphatic regeneration across the obstructive scar tissue during the wound healing process may predispose the tissue to swell at a later date. Treatment for lymphedema remains suboptimal and is in most cases palliative. The purpose of this study was to evaluate the ability of Lymphomyosot to treat tissue swelling and promote lymphangiogenesis in experimental models of murine lymphedema. Experimental models of mouse lymphedema were injected with varied amounts of Lymphomyosot and saline as control. Measurements of tail swelling and wound closure were taken and compared amongst the groups. Three separate groups of mice were analyzed for lymphatic capillary migration, lymphatic vessel regeneration, and macrophage recruitment. Lymphomyosot significantly reduced swelling and increased the rate of surgical wound closure. Lymphomyosot did not increase the migration of lymph capillaries in a mouse tail skin regeneration model or regeneration of lymph vessels following murine axillary lymph node dissection. Lymphomyosot may act through inflammatory and wound repair pathways to reduce experimental lymphedema. Its ability to regulate inflammation as well as assist in tissue repair and extracellular formation may allow for the production of a scar-free matrix bridge through which migrating cells and accumulated interstitial fluid can freely spread.